A team of Stanford University researchers will test a Nektar Therapeutics Inc. drug in a Phase II trial aimed at a common and aggressive form of brain cancer, the company said Tuesday. Dr. Lawrence Recht, a Stanford professor of neurology and neurosurgery, and co-investigators Dr. Seema Nagpal and Dr. Pamela Kunz will test Nektar's etirinotecan pegol in patients with high-grade glioma whose cancer is resistant to GenentechInc.'s Avastin, or bevacizumab.
No comments:
Post a Comment